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Original Article

Intracranial delivery of AAV9 gene therapy
partially prevents retinal degeneration
and visual deficits in CLN6-Batten disease mice
Katherine A. White,1,10 Hemanth R. Nelvagal,2,5,10 Timothy A. Poole,2 Bin Lu,3 Tyler B. Johnson,1,4 Samantha Davis,1
Melissa A. Pratt,1 Jon Brudvig,1 Ana B. Assis,5 Shibi Likhite,6 Kathrin Meyer,7,9 Brian K. Kaspar,7,9
Jonathan D. Cooper,2,5,11 Shaomei Wang,3,11 and Jill M. Weimer1,4,8,11
1Pediatrics

and Rare Diseases Group, Sanford Research, Sioux Falls, SD 57104, USA; 2Pediatric Storage Disorders Laboratory, Division of Genetics and Genomics,

Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA; 3Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los
Angeles, CA 90048, USA; 4Amicus Therapeutics, Philadelphia, PA 19104, USA; 5Department of Pediatrics, The Lundquist Institute at Harbor-UCLA Medical Center
and David Geffen School of Medicine, UCLA, Torrance, CA 90502, USA; 6Nationwide Children’s Hospital. He was involved in AAV9 construct development; 7The
Research Institute at Nationwide Children’s Hospital, Columbus, OH 43205, USA; 8Department of Pediatrics, Sanford School of Medicine, University of South Dakota,
Sioux Falls, SD 57069, USA; 9Department of Pediatrics, The Ohio State University, Columbus, OH 43210, USA

Batten disease is a family of rare, fatal, neuropediatric diseases
presenting with memory/learning decline, blindness, and loss
of motor function. Recently, we reported the use of an
AAV9-mediated gene therapy that prevents disease progression in a mouse model of CLN6-Batten disease (Cln6nclf),
restoring lifespans in treated animals. Despite the success of
our viral-mediated gene therapy, the dosing strategy was optimized for delivery to the brain parenchyma and may limit the
therapeutic potential to other disease-relevant tissues, such as
the eye. Here, we examine whether cerebrospinal ﬂuid (CSF)
delivery of scAAV9.CB.CLN6 is sufﬁcient to ameliorate visual
deﬁcits in Cln6nclf mice. We show that intracerebroventricular
(i.c.v.) delivery of scAAV9.CB.CLN6 completely prevents hallmark Batten disease pathology in the visual processing centers
of the brain, preserving neurons of the superior colliculus, thalamus, and cerebral cortex. Importantly, i.c.v.-delivered
scAAV9.CB.CLN6 also expresses in many cells throughout
the central retina, preserving many photoreceptors typically
lost in Cln6nclf mice. Lastly, scAAV9.CB.CLN6 treatment
partially preserved visual acuity in Cln6nclf mice as measured
by optokinetic response. Taken together, we report the ﬁrst
instance of CSF-delivered viral gene reaching and rescuing pathology in both the brain parenchyma and retinal neurons,
thereby partially slowing visual deterioration.

cated in intracellular trafﬁcking, endocytosis, and lysosomal maintenance, among other cellular functions, and therapeutic approaches
for transmembrane variants are complicated by the inability to
cross-correct neighboring cells.4 At the cellular level, Batten disease
primarily affects the central nervous system (CNS), where lysosomes
accumulate abundant lipofuscin, a chronic neuroimmune response develops, and neurons progressively perish.5 While no cure exists for any
form of Batten disease, enzyme replacement therapy (ERT) effectively
slows progression for some patients of the secreted CLN2 sub-form
(ClinicalTrials.gov: NCT01907087),6,7 and recent clinical trials have
focused on ERTs, small molecule therapies, stem cell therapy, and
gene therapy.5
Gene therapy is an attractive strategy for disorders such as Batten disease, where the function of the disease protein is unknown. We and
others recently characterized the utility of a single, intracerebroventricular (i.c.v.) injection of a self-complementary (sc) adeno-associated virus serotype 9 (AAV9) gene therapy in a mouse model of
variant late infantile CLN6-Batten disease (CLN6 disease), a variant
where patients have biallelic mutations in the CLN6 gene and loss
of the transmembrane protein and present with symptoms in childhood.8,9 Using a Cln6nclf mouse model, it was demonstrated that early
treatment with cerebrospinal ﬂuid (CSF)-mediated delivery of
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INTRODUCTION
Batten disease (neuronal ceroid lipofuscinosis [NCL]) is a family of
rare, fatal, neuropediatric lysosomal storage disorders, typically presenting in early childhood with memory/learning decline, blindness,
and loss of motor function.1,2 Each of these disorders is caused by
mutations in one of thirteen different genes, which encode a variety
of soluble and transmembrane NCL proteins.3 While the function of
these NCL proteins is not entirely understood, some have been impli-
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scAAV9 resulted in near complete prevention of motor, memory/
learning, and survival deﬁcits8. With these preclinical data, a phase
I/II clinical trial was initiated in 2016 (ClinicalTrials.gov:
NCT02725580). Importantly, interim outcome data reported in late
2019 showed stabilization of motor, language, and visual function,
along with a favorable safety proﬁle.10
While our viral-mediated gene therapy for CLN6 disease appears successful, the i.c.v. dosing strategy used in our previous study was optimized for neuronal delivery in the brain parenchyma and may limit
the therapeutic potential to other Batten disease-relevant tissues
such as the eye. As Batten disease patients experience a severe decline
in quality of life as they lose vision and become blind, effective treatments must target critical structures not only in the brain and spinal
cord but also in the retina. Construct targeting and distribution are
highly dependent on the viral vector and serotype, delivery route,
and dosing characteristics (i.e., timing, size, and purity), requiring
careful consideration to yield the most effective transduction of the
most vulnerable cells.11–14 Gene therapies focused on the eye, such
as the US Food and Drug Administration (FDA)-approved Luxturna
(voretigene neparvovec), have generally relied on direct delivery
routes that are most effective in reaching the retina, such as subretinal
or intravitreous delivery routes.13,15 Unfortunately, while these routes
reach the retina, they have limited penetrance to the brain. For multiorgan diseases such as Batten disease, eye-speciﬁc routes of administration would require multiple vectors to be dosed, at minimum, in
parallel to the brain parenchyma, increasing the potential for toxicity,
immune reaction, and other side effects. While more systemic delivery methods, such as intravenous delivery, have been shown to reach
both the eye and brain with a single dose, they require signiﬁcantly
larger doses than other targeted approaches and have been linked
to acute hepato-toxicity and other side effects.16–18
Here, we sought to determine whether a single i.c.v. injection with an
AAV9 gene therapy construct is sufﬁcient to target and prevent the
onset of pathology in both the eye and visual centers of the brain in a
mouse model of variant late infantile CLN6 disease. Cln6nclf mice
were treated at postnatal day 1 (P1) with either PBS or
scAAV9.CB.CLN6. This single CSF-administered dose prevented
Batten disease-associated pathology in visual centers of the brain, expressed in the retina and largely prevented central photoreceptor loss,
and partially preserved visual acuity in Cln6nclf mice. As such, a single,
i.c.v.-mediated administration of scAAV9 is able to express in the retina
and preserve intermediate visual function in addition to its effects in the
brain, which will help optimize gene therapies for CLN6 disease and
other neurodegenerative diseases affecting the retina in the future.

RESULTS
i.c.v. delivery of AAV9-CLN6 prevents Batten disease pathology
in visual centers of the brain

Wild-type and Cln6nclf mice were dosed with scAAV9.CB.CLN6 (5 
1010 viral genomes (vg)/animal, 4 mL volume in phosphate-buffered
saline (PBS)) or PBS (4 mL volume) at P1 via i.c.v. injection as previously described.8 The AAV9 serotype was chosen to preferentially
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target neurons at high efﬁciency when paired with a hybrid
chicken-b-actin (CB) promoter and has previously been shown to
achieve widespread expression of the human CLN6 protein in the
mouse brain.8 Since loss of visual function is a key feature of CLN6
disease, and visual function relies on both the eye and the brain, we
ﬁrst asked whether a single i.c.v. injection of scAAV9.CB.CLN6
impacted Batten disease pathology in visual centers of the brain.
Thalamocortical visual pathways including the dorsal lateral geniculate (DLG) and primary visual cortex (V1) are typically considered to
be key visual pathways in humans and are primarily responsible for
the processing of signals from cone-rich retinal regions with high visual acuity (i.e., the fovea).19 Other areas, such as the superior colliculus (SC), primarily process signals from rod-rich regions located in
the retinal periphery and are important for the detection of movement; in mice, the SC receives projections from 85%–90% of retinal
ganglion cells (RGCs).20,21 Therefore, we analyzed pathology within
the DLG, V1, and SC to investigate two parallel visual information
streams in Cln6nclf mice.
The accumulation of ﬂuorescent lipofuscin within lysosomes is a
cellular signature of Batten disease.5 While the precise impact of
this storage material on disease progression is unknown, its accumulation is often used as a correlate for disease burden.8 Here, we show
pronounced autoﬂuorescent storage material (ASM) accumulation in
Cln6nclf animals in all of the central visual centers of the brain (DLG,
V1, SC), with neonatal scAAV9.CB.CLN6 treatment preventing this
characteristic accumulation at all time points examined (Figure 1).
Collectively, Batten disease is also characterized by a pronounced
and early neuroimmune response in astrocytes and microglia, as evidenced by increases in glial ﬁbrillary acidic protein (GFAP) and cluster of differentiation 68 (CD68) immunoreactivity.5 Similar to ASM
accumulation, Cln6nclf animals presented with robust astrocyte
(GFAP+) and microglial (CD68+) immunoreactivity in all visual centers examined, with scAAV9.CB.CLN6 treatment preventing this
response at all time points examined (Figures 2 and 3, respectively).
Lastly, as CLN6 disease is a neurodegenerative disorder, we asked
whether scAAV9.CB.CLN6 treatment prevented the loss of neurons
in these critical visual centers. Using unbiased stereological counts
on Nissl-stained sections, scAAV9.CB.CLN6 prevented the loss of
neurons in all visual centers examined, at all time points examined
(Figure 4). These results show scAAV9.CB.CLN6’s robust ability to
prevent pathology in visual centers of the brain and, importantly,
shed light on hallmark Batten disease pathology in the SC that has
not previously been characterized in detail for this form of NCL,
despite its presence even at early time points (3 months of age).
i.c.v.-delivered AAV9 expresses in the eye, preserving
photoreceptors in Cln6nclf mice

As neuronal integrity was preserved in the visual processing centers of
the brain in AAV9-treated Cln6nclf mice, we next examined neuronal
integrity in the retina to see if this pathology had also been prevented.
Untreated Cln6nclf mice progressively lost photoreceptors from 3 to
9 months of age (Figures 5A–5C, arrows). In contrast, representative
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Figure 1. CSF delivery of scAAV9.CB.CLN6 prevents classic autofluorescent storage material accumulation in several visual processing centers of the brain
in Cln6nclf mice
(A–C) A single, postnatal day 1 injection of scAAV9.CB.CLN6 delivered via CSF prevents storage material accumulation (ASM, green) in the (A) dorsal lateral geniculate (DLG),
(B) primary visual cortex (V1), and (C) superior colliculus (SC) until 9 months of age. n = 6/treatment for each time point, represented by equal numbers of males and females.
Mean ± SEM, one-way ANOVA for each time point, Bonferroni correction. **p < 0.01, ***p < 0.001, ****p < 0.0001.

images of wild-type animals show 10–12 layers of photoreceptors at
each time point examined, with scAAV9.CB.CLN6 partially preserving these layers in the central retina of Cln6nclf mice until 9 months
of age (Figures 5A–5F). However, photoreceptors in the peripheral
retina continued to be lost following scAAV9.CB.CLN6 treatment
with age, beginning at 3 months of age to 9 months of age (Figures
5D–5F).
Given the unexpected degree of photoreceptor protection in the central retina of Cln6nclf mice treated with an i.c.v. injection of
scAAV9.CB.CLN6, we asked whether human CLN6 was present in

Table 1. Optokinetic tracking sample sizes
Wild type (n)

Cln6nclf (n)

Cln6nclf + scAAV9
(n)

Male

Female

Male

Female

Male

3 months

10

13

13

17

17

11

6 months

7

10

10

12

14

8

9 months

3

3

6

4

11

6

Related to Figure 7.

Female

the retina of treated mice. To characterize the expression patterns
of i.c.v.-delivered scAAV9.CB.CLN6 in the retina, we visualized
endogenous mouse Cln6 transcript (mCln6) and transgenic human
CLN6 (hCLN6) transcript with a modiﬁed in situ technique (RNAscope), as well as hCLN6 protein via immunostaining. A lack of commercial antibodies targeting mouse Cln6 precluded dual immunolabeling. While endogenous mCln6 transcript was present primarily in
the inner and outer nuclear layers, with lower-level expression in
RGCs and the retinal pigmented epithelium (RPE) (Figure 6A),
hCLN6 transcript and protein was expressed widely throughout the
RGC layer, inner nuclear layer, outer nuclear layer, RPE, and choroid,
with particularly robust expression in RGCs (Figures 6B and 6D–6G;
Figure S1). Additionally, hCLN6 immunoreactivity was predominantly present in the central retina, with reduced expression in the
middle and peripheral areas (Figure 6C; Figure S2). When co-labeled
with a marker for photoreceptor outer segments (Rhodopsin [Rho]+),
RGCs (BRN3a+), bipolar cells (PKCa+), and Müller glia (glutamine
synthetase [GS+]), hCLN6 immunolabeling again colocalized primarily with RGCs (Figures 6D–6G), consistent with retinal layer distribution and previous reports of predominantly neuronal expression
following subretinal delivery of AAV9.22 Taken together, a single
i.c.v. injection of scAAV9.CB.CLN6 expresses in the retina and
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Figure 2. CSF delivery of scAAV9.CB.CLN6 prevents increased astrocyte reactivity in the DLG, V1, and SC
(A–C) A single, postnatal day 1 injection of scAAV9.CB.CLN6 delivered via CSF prevents GFAP+ astrocyte reactivity (green) in the (A) DLG, (B) V1, and (C) SC until 9 months of
age. n = 6/treatment for each time point, represented by equal numbers of males and females. Mean ± SEM, one-way ANOVA for each time point, Bonferroni correction. *p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

signiﬁcantly preserves central retinal photoreceptors in Cln6nclf mice,
despite expression patterns that differ somewhat from endogenous
patterns.
i.c.v.-delivered AAV9 significantly preserves visual acuity in
Cln6nclf mice

To assess whether the preservation of retinal and other visual
pathway neurons rescued visual function, animals were tested for visual acuity using optokinetic response from 3 to 9 months of age
(OptoMotry, Cerebral Mechanics) (Figure 7A). Brieﬂy, animals
were individually placed on a platform surrounded by four monitors
arranged in a square, and a gradient of varying contrasts rotated
around the mice in either a clockwise or counterclockwise fashion.
To assess visual acuity, an experimenter blinded to genotype and
treatment status observed the animal and determined whether the
animal was tracking the gradient. Beginning at 6 months of age, untreated Cln6nclf animals of both sexes declined in spatial visual acuity (cycles/degree), with deﬁcits progressing until the last time point
at 9 months of age (Figures 7B and 7C). At 6 and 9 months,
scAAV9.CB.CLN6-treated Cln6nclf mice maintained visual acuity in-
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termediate of untreated Cln6nclf mice and wild-type mice, especially
in female mice, indicating some therapeutic value of i.c.v.-delivered
gene therapy on visual function. Importantly, untreated female
Cln6nclf mice had a signiﬁcantly steeper decline in vision over
the 6-month period when compared to either female
scAAV9.CB.CLN6-treated Cln6nclf or wild-type control mice (Figure 7C, comparison of slope), again supporting a therapeutic effect
of i.c.v.-delivered scAAV9.CB.CLN6 on visual function.

DISCUSSION
In this study we show marked preservation of neurons in both the central retina and central visual pathways of the brain resulting from a single i.c.v. dose of scAAV9.CB.CLN6 to Cln6nclf mice. i.c.v. delivery led to
efﬁcient expression of CLN6 throughout many retinal layers, preserving a signiﬁcant proportion of central retinal photoreceptors and partial visual function in treated Cln6nclf mice until the last time point
examined. Taken together, these data suggest that i.c.v. delivery of
scAAV9.CB.CLN6 effectively protects central visual neurons within
the brain and expresses in the retina, resulting in the partial prevention
of retinal pathology and amelioration of visual decline.
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Figure 3. CSF delivery of scAAV9.CB.CLN6 prevents microglial activation in visual processing centers of the brain
(A–C) A single, postnatal day 1 injection of scAAV9.CB.CLN6 delivered via CSF prevents CD68+ microglial activation (red) in the (A) DLG, (B) V1, and (C) SC until 9 months of
age. n = 6/treatment for each time point, represented by equal numbers of males and females. Mean ± SEM, one-way ANOVA for each time point, Bonferroni correction. *p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Thalamocortical visual pathway pathology is well established in multiple forms of Batten disease including CLN6 and, together with retinal
pathology, has been considered a correlate of the visual failure evident
in many forms of Batten disease.20,24–26 Indeed, in mouse models of
CLN3-Batten disease, pathology is present in the visual thalamocortical
system at 6 months of age despite a lack of retinal neurodegeneration,
suggesting a central thalamocortical cause of visual failure in CLN3 disease mice that perhaps precedes progressive photoreceptor loss in the
retina.20 Until now, the potential involvement of other retinorecipient
nuclei has been overlooked in CLN6 disease.
Our data from untreated Cln6nclf mice reveal for the ﬁrst time progressive neuron loss, ASM accumulation, and glial activation in the
SC, a crucial visual center in mammals that, in mice, receives projections from up to 90% of RGCs.21 i.c.v. delivery of scAAV9.CB.CLN6
effectively prevented pathology in this region, in addition to previously identiﬁed pathology in the visual thalamocortical system
(DLG, V1).26 As these phenotypes were apparent early in Cln6nclf disease progression (3 months of age), these data are additionally indicative of the severity of disease in the SC and its importance in the visual pathway of mice. These results are consistent with the therapeutic
effects of i.c.v. delivery of scAAV9.CB.CLN6 on the somatosensory
thalamocortical system, but the unanticipated beneﬁcial impact of

this treatment upon retinal pathology and visual acuity suggests
this i.c.v. route of administration could potentially provide some
beneﬁt for retinal manifestations of CLN6 disease in lieu of adjunctive
injections directly treating the eye.8
While directing gene therapy to the CSF is a logical approach for treating brain manifestations of disease, it has always been considered unlikely to exert any therapeutic effect upon the retina, as CSF does not
directly contact ocular structures other than the optic nerve.27 Indeed,
prior progress in treating visual manifestations of Batten disease have
relied primarily upon intravitreal delivery of gene, enzyme replacement, or cellular therapies with varying degrees of success.28–31 However, our data reveal that i.c.v.-delivered scAAV9.CB.CLN6 not only
provides hCLN6 expression in the Cln6nclf retina but also partially
rescues retinal pathology, although with the current paradigm this is
predominantly conﬁned to the central retina.
It is not clear why such robust pathological rescue in our study did not
lead to full functional rescue in treated Cln6nclf mice. Although our
approach preserved central retina photoreceptors, peripheral photoreceptors in i.c.v.-treated Cln6nclf mice continued to degenerate with
age, and this process may have impacted visual acuity in older
AAV9-treated Cln6nclf mice. Previous attempts at retinal gene therapy
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in NCL mice have suggested transducing bipolar cells to be important
for preserving photoreceptors and visual function.28,32 In contrast, in
this study hCLN6 expression was mainly observed in the RGC and
photoreceptor layers, with little evidence of bipolar cell expression,
yet this expression pattern preserved considerable numbers of central
photoreceptors and resulted in partial maintenance of visual function.
Therefore, it is possible that both RGCs and bipolar cells have important roles to play in preserving photoreceptor function in Cln6nclf
mice. Additionally, there could be opportunities for improving
hCLN6 expression in cell types that show low levels of expression
in the current study, as there is considerable evidence that AAV9
transduction is more widespread than its product’s transcript or protein expression.33,34
It is also important to note that this study concluded at 9 months of
age and only assessed visual function via optokinetic tracking and not
electroretinography, in which the latter technique gives a more complete and precise picture of the function of the entire retina. Therefore, while our study shows partial preservation of visual function
in AAV9-treated Cln6nclf mice, it is possible that a more thorough longitudinal analysis would point to additional aspects of visual function
that can be improved. Nonetheless, our i.c.v.-treated Cln6nclf mice did
not show any signs of retinal toxicity, as have been reported following
subretinal delivery of various AAV vectors in mice and non-human
primates, suggesting that AAV9 did not adversely affect visual acuity
through cell death in this study.35–37
There are limited data available regarding retinal transduction via
AAV following i.c.v. injection. In the Batten disease ﬁeld, Katz and
colleagues38 treated CLN2 mutant canines with AAV2 via i.c.v. injection, delaying disease progression and improving survival with the
expression of canine CLN2. However, no expression was observed
in the retina of these animals, which suffered from vision loss regardless of pathological improvements in visual centers of the brain. This
may be due to the viral subtype used (AAV2 versus AAV9), animal
species (canine versus murine), or timing of treatment (3 months
of age versus P1), and it is unclear what parameters are necessary
for successful retinal expression via CSF delivery, including interactions between capsid and promoter.39 Importantly, given the differences between visual processes of rodents and humans, our study
will need to be validated in animal models that are more reliant on
the thalamus for visual processing.

Figure 4. i.c.v. delivery of scAAV9.CB.CLN6 prevents neuronal loss in the
DLG, V1, and SC
(A–C) A single, postnatal day 1 injection of scAAV9.CB.CLN6 delivered via CSF
prevents progressive neuronal loss in the (A) DLG, (B) SC, and (C) V1 until 9 months
of age. n = 6/treatment for each time point, represented by equal numbers of males
and females. Mean ± SEM, one-way ANOVA for each time point, Bonferroni
correction. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Our study also does not experimentally explain how CSF-delivered
AAV9 expresses in distantly located cells in the retina. One potential
explanation is that axons of RGCs, which travel from the retina to visual centers of the brain via the optic nerve, may facilitate retrograde
axonal transport of viral particles to cell bodies in the retina. AAV9 is
known to undergo long-distance retrograde transport in CNS neurons, and it readily transduces RGCs.40–42 More difﬁcult to explain,
however, is the expression of hCLN6 in other retinal cell classes
that do not project to the brain. While anterograde transsynaptic
transport of AAV and subsequent products has been described
following intravitreal injection,29,43 including the recent report of
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Figure 5. i.c.v. delivery of scAAV9.CB.CLN6 preserves photoreceptors in Cln6nclf mice
Retinal sections through the optic nerve head stained with cresyl violet show retinal lamination and photoreceptors. (A–C) A single, postnatal day 1 injection of
scAAV9.CB.CLN6 delivered via CSF largely prevents progressive photoreceptor loss in (A) 3 month, (B) 6 month, and (C) 9 month Cln6nclf mice (ONL, arrows). As observed
from representative images, wild-type animals show 10–12 rows of photoreceptor nuclei, while untreated Cln6nclf mice retain only one layer of photoreceptors by 9 months of
age. In contrast, AAV9-treated Cln6nclf mice maintain 7–8 rows of photoreceptors at all time points examined. (D and E) Quantification of photoreceptor density at different
time points is presented in (D), and quantification of photoreceptor density in different retinal areas at 9 months of age is presented in (E). (F) Lastly, retinal montage images
through the optic nerve head show severe photoreceptor loss across the whole retina in untreated Cln6nclf mice at 9 months of age (arrows), while AAV9 treatment substantially preserves photoreceptors across the central retina at the same age (arrows). Peripheral photoreceptors in treated Cln6nclf mice are not preserved at 9 months of age
(arrow). Abbreviations: RGC, retinal ganglion cells; INL, inner nuclear layer; ONL, outer nuclear layer; RPE, retinal pigment epithelium. n = 6/treatment for each time point,
represented by equal numbers of males and females. Mean ± SEM, two-way ANOVA, Tukey correction. ****p < 0.0001.

potential contralateral transfer between eyes in a human gene therapy
trial,44 retrograde transsynaptic transport has not been described, and
other retinal cell classes lack CSF-contacting projections. Lastly, while
the presence of hCLN6 mRNA in our study suggests transsynaptic or
bulk CSF transportation, additional experiments will be required to
elucidate the mechanism of widespread retinal expression following
CSF delivery of AAV9.

described.26 Wild-type animals lacked this mutation. All animal
studies were conducted in an AAALAC (Association for Assessment
and Accreditation of Laboratory Animal Care International)-accredited facility under National Institutes of Health (NIH) guidelines
and approved by Sanford Institutional Animal Care and Use Committee (IACUC; United United States Department of Agriculture license 46-R-0009).

Regardless of the mechanistic details, the demonstration of any
impact upon retinal structure and function in Cln6nclf mice following
i.c.v. delivery of scAAV9.CB.CLN6 is encouraging from a therapeutic
standpoint. Future studies should determine if i.c.v. dosing strategies
can be optimized to maintain peripheral photoreceptor integrity and
full visual acuity and whether delayed dosing strategies can provide
similar beneﬁts. Increased doses, alternative viral serotypes, or combined routes of administration may be necessary to offer the most
complete photoreceptor and visual preservation. Taken together,
this ﬁrst report of CSF-mediated AAV9 delivery to the retina has therapeutic promise and will help determine optimal viral dosing strategies for CLN6 disease and other similar neurodegenerative diseases in
the future.

i.c.v. injection of either scAAV9.CB.CLN6 (5  1010 vg/animal, 4 mL
volume in PBS) or PBS (4 mL volume) was performed on P1 as previously described.8 The injection method and timing were selected
to target speciﬁc neuronal populations that are relevant in CLN6
Batten disease patients. Animals were sedated via hypothermia during
the procedure, monitored until fully recovered, and genotyped as previously described.26

MATERIALS AND METHODS
Ethics statement/animals

Mice were maintained on a C57BL/6J background and housed under
identical conditions. Cln6nclf animals (The Jackson Laboratory,
#003605) had an additional cysteine in exon 4 of the Cln6 gene, resulting in a frameshift mutation and premature stop codon as previously

Tissue analyses

Animals were sacriﬁced at 3, 6, or 9 months of age via CO2 euthanasia
and transcardial perfusion with PBS (n = 3/sex/treatment group for
each time point). Brains were removed and bisected along the midline
into left and right hemispheres. One hemisphere was placed in 4%
paraformaldehyde for 24 h followed by transferring to 30% sucrose
solution overnight for cryoprotection, while the second hemisphere
was bisected again for ﬂash freezing and tissue banking. Eyes were
also removed, cornea punctured, and ﬁxed in 4% paraformaldehyde
for 1 h. Eyes were sunk in a sucrose gradient, beginning at 10% sucrose solution for 1 h, 20% sucrose solution for 1 h, and lastly 30%
sucrose solution overnight.
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Figure 6. i.c.v. delivery of scAAV9.CB.CLN6 expresses throughout the retinal layers, enabling the local translation of hCLN6 in Cln6nclf mouse retinas
(A and B) Endogenous mouse Cln6 (mCln6) expression in a wild-type animal as detected by RNAscope (A) localized primarily to the inner and outer nuclear layers, showing a
different expression pattern as compared to the human CLN6 (hCLN6) transgene (B). (C) Retinal whole-mounts immunolabeled with anti-human CLN6 (red) antibodies
detected hCLN6 primarily in the central retina. Quantification is also shown in (C). (D–F) AAV9-treated Cln6nclf mice immunolabeled with anti-human CLN6 (red) and rhodopsin
(photoreceptor outer segments, green; D), BRN3a (retinal ganglion cells, green; E), PKCa (rod bipolar cells, green; F), or anti-glutamine synthetase (Müller glia, green; G),
show hCLN6 colocalization primarily in RGCs, and also in the INL, ONL, RPE, and choroid. This indicates scAAV9.CB.CLN6 preferentially targeted RGC, INL, ONL, and
epithelial layers using this dosing strategy. n = 6/treatment for each time point, represented by equal numbers of males and females. Mean ± SEM, One-way ANOVA, Tukey
post-hoc. *p<0.05, ****p<0.0001.

4% paraformaldehyde ﬁxed and cryoprotected brains were sectioned
using a Microm H430 freezing microtome (Microm International,
Walldorf, Germany) with a Physitemp BFS 40MOA freezing stage
(Physitemp Instruments, Clifton, NJ, USA) to obtain 40 mm thick coronal sections. A 1 in 6 series of sections was then selected for analysis
of ASM, staining for Nissl substance with cresyl fast violet, and immunohistochemistry, respectively.

Cresyl fast violet staining

Sections were stained for cresyl fast violet as previously described.45,46
Brieﬂy, a 1 in 6 series of 40 mm coronal brain sections were mounted
on slides and air-dried overnight. Slides were stained in 0.05% cresyl
fast violet solution with 10% glacial acetic acid for 1 h at 60 C followed by differentiation in 70%, 80%, 90%, 95%, 100% EtOH, 50/
50% EtOH/xylene, and 100% xylene. Slides were coverslipped using
a xylene-based mountant, DPX.

ping with DAPI (40 ,-diamidino-2-phenylindole-dihydrochloride)
Fluoromount G (SouthernBiotech).
Immunohistochemistry

A 1 in 6 series of 40 mm coronal brain sections were mounted on
slides and brieﬂy air-dried. Slides were blocked in 15% normal
goat serum (Vector Laboratories, Burlingame, CA, USA) in Trisbuffered saline (TBS) with Triton-X (Alfa Aesar, Ward Hill, MA,
USA) followed by simultaneous incubation in primary antibodies
for astrocytes (rabbit polyclonal to GFAP, DAKO cat. no. Z0334,
1:1,000 dilution) and microglia (rat anti-mouse CD68, Bio-Rad,
cat. no. MCA1957, 1:400 dilution). Sections were rinsed in TBS
and incubated in secondary antibody solution (goat anti-rabbit
Alexa Fluor 488, Invitrogen cat. no. A11008, 1:200 dilution and
goat anti-rat 546 Alexa Fluor 546, Invitrogen cat. no. A11081,
1:200 dilution). Slides were rinsed and treated with 1 TrueBlack
(Biotium, cat. no. 23007) before coverslipping with DAPI Fluoromount-G (SouthernBiotech).

Visualization of autofluorescent storage material

A 1 in 6 series of 40 mm coronal brain sections was mounted on to
Superfrost Plus (Thermo Fisher) slides and air-dried before coverslip-
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Eyes were embedded in OCT (optimal cutting temperature compound) and stored at 80 C. Horizontal 10 mm sections were cut
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Figure 7. Cerebrospinal fluid delivery of scAAV9.CB.CLN6 partially maintains visual function in Cln6nclf mice
(A) Schematic of OptoMotry optokinetic tracking equipment. The test mouse sits on a platform surrounded by four monitors that display a rotating virtual gradient, and the
experimenter monitors the animal’s visual tracking using an overhead camera. (B and C) A single, postnatal day 1 injection of scAAV9.CB.CLN6 delivered via CSF partially
restores visual acuity in male (B) and female (C) Cln6nclf mice. When linear fits are compared, untreated female Cln6nclf mice have a significantly steeper decline than both
female wild-type and AAV9-treated Cln6nclf mice (C). Ordinary two-way ANOVA, Tukey correction. For linear fit, slopes were compared using an ordinary one-way ANOVA,
Tukey post hoc. Ns are presented in Table 1. Mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Image in panel (A) obtained from CerebralMechanics
promotional and published materials (http://cerebralmechanics.com/ 23).

on a cryostat (Leica CM1950), with four sections/slide, and were
collected in ﬁve series (50 mm apart). One series was stained with
cresyl violet for assessing retinal lamination and the other sections
were used for immunohistochemistry. Brieﬂy, sections were washed
with PBS, blocked in 2% horse serum and 0.3% Triton X-100, and
incubated with the following primary antibodies overnight at room
temperature: rhodopsin (1:1,000, MAB5356, Millipore), glutamine
synthetase (1:1,000, cat. no. 302, Millipore), Brn-3a (1:250, cat. no.
sc-31984, Santa Cruz), PKCa (1:250, cat. no. sc-208, Santa Cruz),
and human CLN6 (1:250, gift from Stella Lee8). Secondary antibodies
were goat anti-rabbit Cy3 and goat anti-mouse-Alexa 488. Sections
were counterstained with DAPI (Life Technologies). For negative control, sections were treated without primary or secondary antibodies.
RNAscope

Presence of mCln6 transcript and hCln6 transcript were visualized in
retinal sections by RNAscope using the Multiplex Fluorescent V2
Assay kit (ACDBio cat. no. 323110) in accordance with the manufacturer’s protocol. Sections were labeled with either a human CLN6
probe or a mouse Cln6 probe (ACDBio), counterstained with
DAPI, and mounted on slides using an aqueous mounting medium
(Dako Faramount, Agilent).
Imaging and data analysis
Stereological analysis

Estimates of neuron population counts in the DLG nucleus, SC, and
V1 were performed using a design-based optical fractionator method
in a 1 in 6 series of cresyl fast violet stained sections using Stereo
Investigator software (MBF Bioscience).47 Cells were sampled with
counting frames (90  100 mm) distributed over a sampling grid
(DLG, 300  300 mm; SC, 400  400 mm; V1, 600  600 mm) that
was superimposed over the region of interest at 100 magniﬁcation.
Thresholding image analysis

Slides for analysis of ASM and immunohistochemistry were scanned
using a Zeiss Axio Scan.Z1 (Zeiss, Jena, Germany) at 10 magniﬁcation. Scanned images were then analyzed using ImagePro Premier 10

software (Media Cybernetics, Chicago, IL, USA) to manually mark
appropriate anatomical regions (DLG, SC, V1) and to select appropriate unique thresholds for individual antibodies and ASM. Thresholds were applied uniformly across all images of a particular region
and antibody. Results were reported as percentage positive immunoreactivity (or % ﬂuorescence for ASM).
Retinal sections were examined and images taken using a Leica DM
6000B microscope (Leica Microsystems, Wetzlar, Germany) with Jenoptik camera. Photoreceptors were quantiﬁed over a 400 mm length
of retina near the optic head, and quantiﬁcation was performed from
3–5 animals/group. 41 images were obtained from wild-type animals
(3–9 months), 25 images from untreated Cln6nclf animals, and 31 images from Cln6nclf animals + scAAV9.CB.CLN6. Photoreceptors were
counted and analyzed using ImageJ threshold and analyze particles
functions. The number of photoreceptor layers was gathered from
representative images, counting the number of nuclei across the outer
nuclear layer. Photoreceptor layer metrics are representative observations, rather than direct quantiﬁcations.
CLN6 antibody-stained retinal whole-mounts were evaluated and
imaged with an Olympus BX51 Upright Microscope. Twelve images/retina (3 images from central, middle, and peripheral parts of
the retina from each quarter, as illustrated in Figure S1) were taken
from each retina (n = 3) with ﬂuorescence microscope at 10 magniﬁcation. The quantiﬁcation of ﬂuorescent signals was performed using ImageJ software (NIH) with the threshold and the analyze particles functions.
Optokinetic response

At 3, 6, and 9 months of age, male and female Cln6nclf and wild-type
mice were placed in an OptoMotry optokinetic tracking chamber
(Cerebral Mechanics, http://cerebralmechanics.com/).23 Brieﬂy, the
chamber consisted of four computer monitors facing the animal, displaying a rotating black and white contrast gradient. Blinded experimenters observed whether the animal appeared to see the gradient by
intentional head tracking and scored the animal accordingly using
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Cerebral Mechanics software. Visual acuity was averaged from both
eyes in cycles/degree. n = 11–17 animals/sex at 3 months of age;
n = 5–15 animals/sex at 6 months of age; n = 3–11 animals/sex at
9 months of age.
Statistical analysis

6. Lewis, G., Morrill, A.M., Conway-Allen, S.L., and Kim, B. (2020). Review of
Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for LateInfantile Neuronal Ceroid Lipofuscinosis Type 2. J. Child Neurol. 35, 348–353.
7. Schulz, A., Ajayi, T., Specchio, N., de Los Reyes, E., Gissen, P., Ballon, D., Dyke, J.P.,
Cahan, H., Slasor, P., Jacoby, D., and Kohlschütter, A.; CLN2 Study Group (2018).
Study of Intraventricular Cerliponase Alfa for CLN2 Disease. N. Engl. J. Med. 378,
1898–1907.

Speciﬁc statistical tests were calculated using Graphpad Prism and are
described in each ﬁgure legend. All graphs are represented as mean ±
SEM; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

8. Cain, J.T., Likhite, S., White, K.A., Timm, D.J., Davis, S.S., Johnson, T.B., DennysRivers, C.N., Rinaldi, F., Motti, D., Corcoran, S., et al. (2019). Gene Therapy
Corrects Brain and Behavioral Pathologies in CLN6-Batten Disease. Mol. Ther 27,
1836–1847.
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